Janux Therapeutics Stock Analysis
| JANX Stock | USD 48.52 6.46 11.75% |
Janux Therapeutics is overvalued with Real Value of 34.41 and Target Price of 27.25. The main objective of Janux Therapeutics stock analysis is to determine its intrinsic value, which is an estimate of what Janux Therapeutics is worth, separate from its market price. There are two main types of Janux Therapeutics' stock analysis: fundamental analysis and technical analysis.
The Janux Therapeutics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Janux Therapeutics is usually not traded on Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day, Thanksgiving Day. Janux Stock trading window is adjusted to America/New York timezone.
Janux |
Janux Stock Analysis Notes
About 99.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 1.2. Janux Therapeutics had not issued any dividends in recent years. Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager platform technology to treat patients suffering from cancer. The company was incorporated in 2017 and is headquartered in La Jolla, California. Janux Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 56 people. To learn more about Janux Therapeutics call David Campbell at 858-751-4493 or check out https://www.januxrx.com.Janux Therapeutics Investment Alerts
| Janux Therapeutics had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 8.08 M. Net Loss for the year was (58.29 M) with loss before overhead, payroll, taxes, and interest of (44.83 M). | |
| Janux Therapeutics currently holds about 338.76 M in cash with (50.58 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.15. | |
| Janux Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Over 99.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: Janux Therapeutics, Inc. Receives Average Recommendation of Moderate Buy from Brokerages - MarketBeat |
Janux Therapeutics Upcoming and Recent Events
Earnings reports are used by Janux Therapeutics to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period..
| 8th of March 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 8th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Janux Largest EPS Surprises
Earnings surprises can significantly impact Janux Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2022-08-09 | 2022-06-30 | -0.37 | -0.41 | -0.04 | 10 | ||
2022-05-10 | 2022-03-31 | -0.37 | -0.32 | 0.05 | 13 | ||
2023-05-09 | 2023-03-31 | -0.49 | -0.42 | 0.07 | 14 |
Janux Therapeutics Environmental, Social, and Governance (ESG) Scores
Janux Therapeutics' ESG score is a quantitative measure that evaluates Janux Therapeutics' performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Janux Therapeutics' operations that may have significant financial implications and affect Janux Therapeutics' stock price as well as guide investors towards more socially responsible investments.
Janux Stock Institutional Investors
| Shares | Geode Capital Management, Llc | 2024-03-31 | 467.5 K | State Street Corporation | 2024-03-31 | 399.5 K | Avidity Partners Management Lp | 2024-03-31 | 384.2 K | Samlyn Capital, Llc | 2024-03-31 | 296.4 K | Two Sigma Investments Llc | 2024-03-31 | 224.7 K | Northern Trust Corp | 2024-03-31 | 202 K | Alyeska Investment Group, L.p. | 2024-03-31 | 193 K | Driehaus Capital Management Llc | 2024-03-31 | 191.1 K | Samsara Biocapital, Llc | 2024-03-31 | 180.2 K | Ra Capital Management, Llc | 2024-03-31 | 9.2 M | Fmr Inc | 2024-03-31 | 7.7 M |
Janux Market Capitalization
The company currently falls under 'Mid-Cap' category with a current market capitalization of 2.7 B.Janux Profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.15) | (0.16) | |
| Return On Capital Employed | (0.20) | (0.19) | |
| Return On Assets | (0.15) | (0.16) | |
| Return On Equity | (0.17) | (0.16) |
Management Efficiency
Janux Therapeutics has return on total asset (ROA) of (0.0874) % which means that it has lost $0.0874 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.115) %, meaning that it created substantial loss on money invested by shareholders. Janux Therapeutics' management efficiency ratios could be used to measure how well Janux Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.16 in 2024. Return On Capital Employed is likely to rise to -0.19 in 2024. At this time, Janux Therapeutics' Net Tangible Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 32.7 M in 2024, whereas Total Assets are likely to drop slightly above 251.1 M in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 7.82 | 8.21 | |
| Tangible Book Value Per Share | 7.82 | 8.21 | |
| Enterprise Value Over EBITDA | (6.72) | (7.06) | |
| Price Book Value Ratio | 1.37 | 1.44 | |
| Enterprise Value Multiple | (6.72) | (7.06) | |
| Price Fair Value | 1.37 | 1.44 | |
| Enterprise Value | 477.6 M | 850.2 M |
The analysis of Janux Therapeutics' management efficiency is an essential part of evaluating and assessing the financial and operational performance of the entity. It is also vital to analyze Janux Therapeutics' future growth prospects and the overall market conditions to determine the value and potential of its stock. The analysis involves studying a range of financial metrics such as revenue, earnings, profit margins, cash flow, debt, market share, and external factors such as economic trends, industry outlook, competition, and government regulations. The goal of Janux Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions.
Beta 3.869 |
Technical Drivers
As of the 5th of June, Janux Therapeutics retains the Market Risk Adjusted Performance of 11.5, downside deviation of 4.57, and Risk Adjusted Performance of 0.0274. Janux Therapeutics technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices.Janux Therapeutics Price Movement Analysis
The output start index for this execution was thirteen with a total number of output elements of fourty-eight. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Janux Therapeutics middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Janux Therapeutics. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Janux Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Janux Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Janux Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Janux Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Ra Capital Management, L.p. over three months ago Acquisition by Ra Capital Management, L.p. of 1397849 shares of Janux Therapeutics at 0.001 subject to Rule 16b-3 | ||
Meyer Andrew Hollman over three months ago Acquisition by Meyer Andrew Hollman of 105000 shares of Janux Therapeutics subject to Rule 16b-3 | ||
Lichter Jay over six months ago Purchase by Lichter Jay of 849854 shares of Janux Therapeutics | ||
Ra Capital Management Lp over six months ago Purchase by Ra Capital Management Lp of 495008 shares of Janux Therapeutics | ||
Lichter Jay over six months ago Acquisition by Lichter Jay of 12500 shares of Janux Therapeutics subject to Rule 16b-3 | ||
Meyer Andrew Hollman over a year ago Acquisition by Meyer Andrew Hollman of 106750 shares of Janux Therapeutics subject to Rule 16b-3 | ||
Meyer Andrew Hollman over a year ago Acquisition by Meyer Andrew Hollman of 90000 shares of Janux Therapeutics subject to Rule 16b-3 |
Janux Therapeutics Predictive Daily Indicators
Janux Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Janux Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 229911.0 | |||
| Daily Balance Of Power | (0.90) | |||
| Rate Of Daily Change | 0.88 | |||
| Day Median Price | 51.27 | |||
| Day Typical Price | 50.35 | |||
| Price Action Indicator | (5.98) | |||
| Period Momentum Indicator | (6.46) | |||
| Relative Strength Index | 45.27 |
Janux Therapeutics Corporate Filings
8K | 8th of May 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 29th of April 2024 Other Reports | ViewVerify | |
8K | 8th of March 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 6th of March 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F4 | 4th of March 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
FWP | 29th of February 2024 A written communication used by offering participants to offer securities to the public or to solicit securities transactions. | ViewVerify |
| 28th of February 2024 Other Reports | ViewVerify | |
8K | 27th of February 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
Janux Therapeutics Forecast Models
Janux Therapeutics' time-series forecasting models are one of many Janux Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Janux Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Janux Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Janux Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Janux shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Janux Therapeutics. By using and applying Janux Stock analysis, traders can create a robust methodology for identifying Janux entry and exit points for their positions.
| Last Reported | Projected for Next Year | ||
| Pretax Profit Margin | (7.21) | (7.57) | |
| Operating Profit Margin | (9.03) | (9.48) | |
| Net Loss | (7.21) | (7.57) | |
| Gross Profit Margin | 0.76 | 0.97 |
Current Janux Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Janux analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Janux analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
| Target Price | Advice | # of Analysts | |
| 27.25 | Strong Buy | 10 | Odds |
Most Janux analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Janux stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Janux Therapeutics, talking to its executives and customers, or listening to Janux conference calls.
Janux Stock Analysis Indicators
Janux Therapeutics stock analysis indicators help investors evaluate how Janux Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Janux Therapeutics shares will generate the highest return on investment. By understating and applying Janux Therapeutics stock analysis, traders can identify Janux Therapeutics position entry and exit signals to maximize returns.
| Begin Period Cash Flow | 52.2 M | |
| Common Stock Shares Outstanding | 44 M | |
| Total Stockholder Equity | 344.3 M | |
| Property Plant And Equipment Net | 27.8 M | |
| Cash And Short Term Investments | 344 M | |
| Cash | 19.2 M | |
| Accounts Payable | 2.4 M | |
| Net Debt | 5.3 M | |
| 50 Day M A | 47.749 | |
| Total Current Liabilities | 13 M | |
| Other Operating Expenses | 81.1 M | |
| Non Current Assets Total | 31.2 M | |
| Non Currrent Assets Other | 3.3 M | |
| Stock Based Compensation | 20 M |
Additional Tools for Janux Stock Analysis
When running Janux Therapeutics' price analysis, check to measure Janux Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Janux Therapeutics is operating at the current time. Most of Janux Therapeutics' value examination focuses on studying past and present price action to predict the probability of Janux Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Janux Therapeutics' price. Additionally, you may evaluate how the addition of Janux Therapeutics to your portfolios can decrease your overall portfolio volatility.